絞り込み

16735

広告

Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-infusion vancomycin.

著者 Ma NH , Walker SAN , Elligsen M , Kiss A , Palmay L , Ho G , Powis J , Bansal V , Leis JA
J Antimicrob Chemother.2020 Jan 09 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

Patients with good renal function receiving intermittent-infusion vancomycin (IIV) may require total daily doses ≥4 g to achieve trough concentrations of 15-20 mg/L, increasing the risk of vancomycin-associated nephrotoxicity. Continuous-infusion vancomycin (CIV) may be associated with a lower risk of vancomycin-associated nephrotoxicity compared with IIV, but studies comparing safety of both dosing strategies are lacking.
PMID: 31919504 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード